Article metrics

Download PDFPDF
Extended report
Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles

 

Online download statistics by month:

Online download statistics by month: August 2017 to April 2022

AbstractFullPdf
Aug 20174746263192
Sep 20175616961
Oct 201796813595
Nov 20174777863
Dec 20173616060
Jan 20182766046
Feb 20183844650
Mar 20182635133
Apr 20183127631
May 20182593418
Jun 20181892220
Jul 20181903222
Aug 20182203623
Sep 20181703726
Oct 20181784430
Nov 20182302723
Dec 2018266235
Jan 20192143514
Feb 20192202517
Mar 20191592110
Apr 20191813717
May 20191972615
Jun 20191922010
Jul 20191312510
Aug 2019114103
Sep 201998106
Oct 2019166117
Nov 2019971911
Dec 2019130115
Jan 2020120147
Feb 20201511612
Mar 2020202147
Apr 2020125128
May 2020159159
Jun 2020113127
Jul 20201091814
Aug 202011294
Sep 20201641413
Oct 2020951910
Nov 20201171515
Dec 2020106118
Jan 2021117108
Feb 202115464
Mar 20212331515
Apr 20211991911
May 20215184
Jun 2021986
Jul 2021982
Aug 20211195
Sep 202126229
Oct 20219873
Nov 2021119113
Dec 202111353
Jan 202214666
Feb 202213263
Mar 2022152147
Apr 202215664
Total1524716721130